Compare GLU & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GLU | BHST |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.3M | 117.2M |
| IPO Year | N/A | N/A |
| Metric | GLU | BHST |
|---|---|---|
| Price | $19.83 | $4.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 12.4K | ★ 40.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $32,720,000.00 |
| Revenue This Year | N/A | $116.40 |
| Revenue Next Year | N/A | $55.91 |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | N/A | ★ 45.88 |
| 52 Week Low | $11.61 | $4.72 |
| 52 Week High | $15.40 | $12.80 |
| Indicator | GLU | BHST |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 36.17 |
| Support Level | $19.43 | $5.08 |
| Resistance Level | $20.00 | $5.56 |
| Average True Range (ATR) | 0.33 | 0.36 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 57.90 | 0.00 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.